首页> 美国卫生研究院文献>Tissue Engineering. Part A >Cell-Seeded Adhesive Biomaterial for Repair of Annulus Fibrosus Defects in Intervertebral Discs
【2h】

Cell-Seeded Adhesive Biomaterial for Repair of Annulus Fibrosus Defects in Intervertebral Discs

机译:修复椎间盘纤维环缺损的细胞种子粘性生物材料

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Defects in the annulus fibrosus (AF) of intervertebral discs allow nucleus pulposus tissue to herniate causing painful disability. Microdiscectomy procedures remove herniated tissue fragments, but unrepaired defects remain allowing reherniation or progressive degeneration. Cell therapies show promise to enhance repair, but methods are undeveloped and carriers are required to prevent cell leakage. To address this challenge, this study developed and evaluated genipin-crosslinked fibrin (FibGen) as an adhesive cell carrier optimized for AF repair that can deliver cells, match AF material properties, and have low risk of extrusion during loading. Part 1 determined that feasibility of bovine AF cells encapsulated in high concentration FibGen (F140G6: 140 mg/mL fibrinogen; 6 mg/mL genipin) for 7 weeks could maintain high viability, but had little proliferation or matrix deposition. Part 2 screened tissue mechanics and in situ failure testing of nine FibGen formulations (fibrin: 35–140 mg/mL; genipin: 1–6 mg/mL). F140G6 formulation matched AF shear and compressive properties and significantly improved failure strength in situ. Formulations with reduced genipin also exhibited satisfactory material properties and failure behaviors warranting further biological screening. Part 3 screened AF cells encapsulated in four FibGen formulations for 1 week and found that reduced genipin concentrations increased cell viability and glycosaminoglycan production. F70G1 (70 mg/mL fibrinogen; 1 mg/mL genipin) demonstrated balanced biological and biomechanical performance warranting further testing. We conclude that FibGen has potential to serve as an adhesive cell carrier to repair AF defects with formulations that can be tuned to enhance biomechanical and biological performance; future studies are required to develop strategies to enhance matrix production.
机译:椎间盘纤维环(AF)的缺陷使髓核组织突出,导致疼痛性残疾。显微椎间盘切除术可去除椎间盘突出的组织碎片,但未修复的缺损仍可进行椎间盘突出或进行性变性。细胞疗法显示出有望增强修复的前景,但方法尚不完善,需要载体来防止细胞渗漏。为了应对这一挑战,本研究开发并评估了Genipin交联纤维蛋白(FibGen),它是一种针对AF修复而优化的粘附性细胞载体,可以修复细胞,传递AF材料的特性,并且在加载过程中挤出的风险较低。第一部分确定了用高浓度FibGen(F140G6:140μmg/ mL纤维蛋白原;6μmg/ mL genipin)封装的牛AF细胞可持续7周的可行性,但几乎没有增殖或基质沉积。第2部分筛选了9种FibGen制剂的组织力学和原位失效测试(血纤蛋白:35–140μmg / mL;京尼平:1–6μmg / mL)。 F140G6配方具有AF剪切和压缩特性,并显着提高了原位破坏强度。具有减少的尼尼平的制剂还表现出令人满意的材料性能和失效行为,需要进一步的生物学筛选。第3部分筛选了封装在四种FibGen制剂中的AF细胞1周,发现降低的Genipin浓度可提高细胞活力和糖胺聚糖的产生。 F70G1(70µmg / mL纤维蛋白原; 1µmg / mL genipin)表现出平衡的生物学和生物力学性能,值得进一步测试。我们得出的结论是,FibGen具有作为粘附细胞载体的潜力,其具有可调整以增强生物力学和生物性能的配方来修复AF缺陷。需要未来的研究来开发提高基质产量的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号